



सत्यमेव जयते



क.रा.बी.नि.  
ESIC

कर्मचारी राज्य बीमा निगम  
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)  
EMPLOYEES' STATE INSURANCE CORPORATION  
(Ministry of Labour & Employment, Govt. of India)

**DG-ESIC CENTRAL RATE CONTRACT NO. – 164  
FOR SUPPLY OF DRUGS**

(VALID FROM 8<sup>th</sup> APRIL, 2025 to 7<sup>th</sup> APRIL, 2027)

DRUGS FROM NATIONAL LIST OF ESSENTIAL MEDICINES (NLEM)

STRICTLY FOR OFFICIAL USE

मुख्यालय/HEADQUARTERS'

कमरा नंबर 312 और 321, तीसरी मंजिल, पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002

Room No. 312 & 321, 3<sup>rd</sup> Floor, Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002

[www.esic.gov.in](http://www.esic.gov.in), ☎ 011-23604773, ✉ [dmc-rc@esic.gov.in](mailto:dmc-rc@esic.gov.in)



क.रा.बी.नि.  
ESIC

S.No.	Contents	Page No.
1.	Forwarding letter along with terms & conditions for operation of Rate Contract No. 164	1-12
2.	List of Approved Pharmaceutical firms of Rate Contract No. 164	13-18
3.	Indexing of approved Items	19-24
4.	Rate Schedule of Rate Contract No. 164	25-45

क.रा.बी.नि.  
ESIC

*[Handwritten signature]*

**STRICTLY FOR OFFICIAL USE ONLY**



कर्मचारी राज्य बीमा निगम  
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)  
EMPLOYEES' STATE INSURANCE CORPORATION  
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS'  
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002  
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002 [www.esic.gov.in](http://www.esic.gov.in),  
☎011-23604773, ✉ [dmc-rc@esic.gov.in](mailto:dmc-rc@esic.gov.in)

No. U-25/12/RC/159TO163/2022-Med.V (E-117064)/164

Dt: 8<sup>th</sup> April 2025

From:

The Director General,  
E.S.I. Corporation,  
Panchdeep Bhawan,  
C.I.G Road,  
NEW DELHI - 110 002.

To

Director (Medical) Delhi/Noida  
Dean-PGIMSR's/ All ESIC Medical Colleges & Hospitals/Dental Colleges  
Medical Superintendent – All ESIC & ESIS Hospitals,  
Director, ESI Scheme – All States & UTs.

Sub:

**PROCUREMENT OF DRUGS UNDER ESIC CENTRAL RATE CONTRACT NO. 164  
EFFECTIVE FROM 08.04.2025 TO 07.04.2027.**

Sir / Madam,

Please find enclosed a copy of the DG-ESIC Centralized Rate Contract duly adhering to Public Procurement (Preference to Make in India) Order, 2017 (as amended and revised till date) and related notifications from the relevant Nodal Ministry/ Department, finalized for supply of Drugs under the ESI Scheme in the country.

**Validity of this Rate Contract is for a period of two years i.e. w.e.f. 08.04.2025 TO 07.04.2027.**

Further, the following terms & conditions are issued to govern operation of the Rate Contract:-

1. Immediately on receipt of this communication, the Chief Direct Demanding Officers- Medical Superintendent/Dean/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his/her behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.

2. Supply orders will be placed by Medical Superintendents/Deans/Director, Insurance Medical Services of various States, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and / or wherever specifically provided in the terms & conditions of the Rate Contract. The Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract.
3. All the supply orders shall be signed only by the officers who have been duly authorised and included in the list of DDOs. DDOs will send scanned copy of the Purchase Order mandatorily through email followed by speed post directly to the Approved Pharmaceutical Firm. The due date of delivery will be counted from the date of issuance of purchase order via email. It shall be the responsibility of DDOs to monitor the activity of placing purchase order via email/online module.
4. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them.
5. The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report along with the comments and details as under: -

**PROFORMA FOR NON-SUPPLY REPORT**

R.C. No.	Item No. & Name of Drug	Name of firm	S.O. No. with Date	Preference (L1/L2/L3)	Qty. not supplied	Risk Purchase/ penalty levied	Payment if pending	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.

6. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.
7. It will be ensured before placing order by the Direct Demanding Officer that necessary funds are available and payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.
8. Supply orders/Purchase order(s) will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.



9. No guarantee can be given as to the minimum quantity which will be drawn against this contract but the approved Pharmaceutical firm will supply quantity as may be ordered by the Direct Demanding Officers during the currency of the contract.
10. The approved Pharmaceutical firm will supply the items immediately on demand or latest within six weeks of placing of supply order throughout the period of contract.
11. Supply orders/Purchase orders against the contract will be accepted as long as these reach the approved Pharmaceutical firm on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.
12. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm to supply the item as per the specifications of the relevant rate contract.

### **SUPPLIES**

13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.
14. During transit approved Pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.
15. The prices approved are F.O.R. Destination per unit and are exclusive of GST except where indicated but inclusive of all charges for packing and forwarding.
16. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.
17. **The approved** Pharmaceutical firm will have to supply drugs directly in the quantity ordered, to ESIC or ESIS Institutions. The approved Pharmaceutical firm shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons. In case, at any stage of the contract, it is found that the approved Pharmaceutical firm has appointed the distributors/dealers/third party agent for making supply or receiving of supply order against the contract, ESI Corporation will initiate the following actions against the approved Pharmaceutical firm(s):

- a. 100% forfeiture of Performance Security from the valid current all DG-ESIC Rate Contract(s).
- b. Blacklisting for participation in the future tender enquiries for all ESI Institutions for a period of two years prospectively.

18. Marking:

Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.

19. Packing:

- a) It should be ensured that all labels of cartons, ampoules, vials, bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted/rubber stamping with indelible ink clearly. Any consignment without such stamping will not be considered valid and will be rejected.
- b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.
- c) Supplies to be made in proper boxes.
- d) Liquid orals to be supplied only in glass/ plastic bottles conforming to Drugs & Cosmetics Act and rules made there under.
- e) Large volume parenterals to be supplied only in plastic bottles / polypacks conforming to Drugs & Cosmetics Act and rules made there under.
- f) It should be ensured that only **first use packaging material of uniform size including Bottles and vials** should be used for making supplies on the basis of ESI Rate Contract.
- g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.
- h) Packing should be able to prevent damage or deterioration during transit.
- i) All containers i.e. bottle, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents. MRP should not be written on any labels otherwise it will be disqualified.
- j) All DGESIC approved pharmaceutical firm will make supply bearing Quick response code on its label at each level packaging that store data or information readable with software application to facilitate tracking and tracing as per Gazette Notification and CDSO guidelines time to time.

**20. Life Period :**

I:

- a) For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture.
- b) For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture.
- c) Imported Drugs: As on the date of delivery, Drugs should have a minimum 50% of valid shelf life from the date of manufacture.

II.

Notwithstanding the above, DDOs/Authorized nominated officer by DDO may relax this criteria in case of exigencies with reasons duly recorded and shall be responsible for use of that stores within its given shelf life, with a suitable undertaking from the supplier, the terms of which shall be decided by the consignee as per the requirement of the stores and usage pattern. The Consignee should ensure that there should not be any financial loss to the Corporation.

**21. Pharmacopoeia Specifications:**

Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation supplied as per the provisions of Drug and Cosmetics Act.

22. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.

23. It should be ensured that ISI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has ISI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards.

**24. Testing of Drugs – Quality Control**

- a. Approved Rate Contract Holder should mandatorily submit a Test Report for that particular batch of medicines tested by the Government/Government approved Laboratories along with each supply, failing which supply received will be liable for rejection at the inspection stage and penalty of late supply will be levied as per provisions.
- b. Regular testing of 10% of supplies of drugs received in a month will be under taken by ESI from Govt./Govt. approved laboratories. Additional quality testing may also be undertaken by ESI Institutions at any time during the shelf life or whenever any defect is noticed.

- c. Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the approved Pharmaceutical firm/ firms at regular interval to maintain and ensure the quality of drugs.
- d. Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.
- e. The report of the Govt./Govt. approved laboratory shall be accepted by the approved Pharmaceutical firm. In case the same is disputed by the approved Pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However, the same should be submitted **within three months**, from the date of communication of the disputed test report to the approved Pharmaceutical firm. For this, the approved Pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory **at their own cost**. In case no response is received from the approved Pharmaceutical firm within the stipulated period, action as deemed fit as per terms & conditions of the Rate Contract will be initiated.
- f. For imported items: - The approved Pharmaceutical firm must submit the In-house test report of Principal manufacturer with each and every batch of supply.
- g. If any drug/s supplied against this Rate Contract are found to be "Not of Standard Quality" on inspection by Competent Authority, the approved Pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise risk purchase will be charged from the approved Pharmaceutical firm/s.
- h. If the product is found to be "Not of Standard Quality", the cost of testing will be recovered from the approved Pharmaceutical firms and further action will be taken as per clause no. 25 mentioned below:
25. The classification of defects into different categories is as per the guidelines issued by the Drugs Controller General (India), Central Drugs Standard Control Organization (CDSCO) & action will be taken by ESIC for each category of defects, described as below: -
- A. CATEGORY 'A' DEFECT (Spurious / Adulterated Drugs)-**
- If any item / Batch of the item declared Not of Standard quality (NSQ) under Category A .**
- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Recoveries to be initiated by the DDO's wherever payment had been made already.
  - **100% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for all the quoted drugs.



- Debarring of the Rate Contract holder /approved Pharmaceutical firm from current and all future DGESIC Rate Contract for participation in tender enquiry of all ESIC institutions prospectively for a period of two years.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.

**B. CATEGORY 'B' DEFECT (Grossly Substandard Drugs)**

**1. If single item/ Batch of item is declared NSQ under Category B**

- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **20% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for that drug as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item.
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

**2.**

**a) If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category B**

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **50% (20% + 30%) Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2<sup>nd</sup> NSQ) as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- **Any subsequent (3<sup>rd</sup> onwards) NSQ reported** of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current and all future DGESIC Rate Contracts for a period of two years for participation in all ESI Institutions prospectively along with forfeiture of **100% performance security for all NSQ declared items.**

- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
- b) **If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category B within a year**
  - Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
  - **100% Forfeiture of Performance Security from the respective DGESIC Rate Contract for this item (2<sup>nd</sup> NSQ) as per clause 13(III) of TE.**
  - Debarring of Rate Contract Holder/approved Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for the item for a period of two years for participation in all ESI Institution prospectively.
  - Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

#### C. CATEGORY ' C ' DEFECT (Minor Defects)

##### 1.If single item/ Batch of item is declared NSQ under Category C

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

2.

##### a)If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category-C.

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Warning to be issued to the firm for the NSQ item.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

##### b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category C within a year.

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **10% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2<sup>nd</sup> NSQ) as per clause 13(III) of TE.
- **Any subsequent (2<sup>nd</sup> NSQ onwards)** NSQ reported of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current DGESIC Rate Contracts.
- Warning to be issued to the firm for the NSQ item
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

26. **Delivery Period – Risk Purchase**

- a. Delivery period will be of six weeks from the date of issuance of purchase order via email and the approved Pharmaceutical firm shall execute the order within stipulated time.
- b. If the approved Pharmaceutical firm fails to execute the supply order within the stipulated period of six weeks, a penalty of two (2) percent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. An approved Pharmaceutical firm can seek extension of the delivery period with the prior consent of the Direct Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. The extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned DDO.
- c. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other approved Pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate or from local chemist. All DDOs of ESIC & ESIS Institutions shall record each instance of Non-Supply of respective approved Pharmaceutical Firm and a consolidated quarterly non-supply report to be submitted at ESIC HQRS.

**Extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.**



- d. i) If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of approved Pharmaceutical firm. **The extra expenditure involved in procuring supplies from elsewhere i.e. L2 firm/other running Govt. Contract/ Local Purchase etc. will be recoverable from the approved Non-supplying Pharmaceutical firm, in full by Direct Demanding Officers.**
- ii) The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with bidder by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the bidder's Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than two years.
- e. If the approved Pharmaceutical firm fails to execute the supply order three times at any location of ESIC & ESIS in any part of the country during the period of rate contract, it shall be debarred for the next two years with effect from the last failure and forfeiting of Performance Security for that drug.

27. **Payment**

Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm/bidder to supply the items as per the specifications of the relevant rate contract. No claim for the payment from contractor shall be entertained after the lapse of three years of arising of the claim.

28. Any dues or payments that have arisen to the Corporation from the approved Pharmaceutical firm for which no specific time limit has been laid down in the terms and conditions shall be payable by the approved Pharmaceutical firm within such time limit as may be prescribed in the letters/orders addressed to the approved Pharmaceutical firms.
29. Any payments that have been demanded as per the provisions of above-mentioned clause or under any other clause shall be payable within the time laid down. On failure to do so:
- The approved Pharmaceutical firm shall be liable to be debarred for supplying items/ drugs etc. to the Corporation for a period not exceeding two years.
  - The Corporation reserves its right to take appropriate legal action against the defaulting firms as may be legally advised, including claim for compensation and damages for the period of delay and / or simple interest 10% per annum for each day of default.

30. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed: -
- (a) Items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.
- (b) In case of items, where two approved Pharmaceutical Firms exist at L-1(1<sup>st</sup> Preference), it is mandatory for all Direct Demanding Officers (DDOs) to place Supply Orders in the ratio of 50% of the order quantity to each L-1 approved Pharmaceutical firm on each instance of placing of supply order in adherence to Public Procurement (Preference to Make in India) Order, 2017 guidelines issued vide order dated 16.09.2020.
31. No other document should be entertained for giving any cognizance for placing the supply orders.
32. The validity of the contract of approved Pharmaceutical firm holding Patent right of approved drug/s in the currency of Rate Contract shall be for two years or till date of expiry of patent whichever is earlier. It is the sole responsibility of the patent holding firm to mandatorily inform ESIC Ten days before the expiry of the Patent of the approved drug/s in Rate Contract, failing which the participating firm shall be blacklisted in the participating and prospective RCs for a period of two years alongwith forfeiture of EMD/ Performance security (as the case may be) as per Terms & Conditions of the Tender Enquiries.
33. The Letter of Award issued to the firms by this office cannot be used for placing orders.
34. Standing Committee on Government e-Market (SCoGeM), Ministry of Labour & Employment has granted exemption to publish and operate DG-ESIC Rate Contract for the Drugs other than drugs reserved for CPSUs.
35. Force Majeure:  
If at any time during the applicability of Contract the bidder fails to discharge its Obligation due to force majeure (natural disaster or act of God etc.) he will promptly notify the Director General or its representative about the happening of such an event. The Director General or its representative is solely entitled to terminate/ determine the order/contract in respect of such performance of the bidder(s) obligations if he so desires. The obligations under the contract on behalf of bidder for the contract shall be resumed as soon as practicable after the event has come to an end or ~~ceased~~ to exist.

36. It shall be the sole responsibility of Medical Superintendents/Deans/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO/ Head of Institutions of respective State to maintain an optimum Inventory level with strict control as per ABC-VED matrix and ensure the drug formulary of the respective institution is followed in right earnest to provide medical services to ESI Beneficiaries.
37. All Deans/MSs/ DIMS/ Head of ESIC & ESIS Institutions are requested to keep a vigilant check on procurement of drugs in order to avoid obsolescence/expiry/excessive procurement of drugs resulting in infructuous expenditure.


**This issue with the approval of Competent Authority.**

**Encl.: As above.**


**Copy to:**

1. PPS/PS to Director General, ESIC for information.
2. PPS/PS to Finance Commissioner for information.
3. PPS/PS to Medical Commissioner (Procurement/ Medical Services/ Medical Education / Medical Administration) for information.
4. Accounts Branch – V (Hqrs. Office)
5. All Chief Direct Demanding Officers (In-Charge) of ESIC and ESI Scheme of all States/UT's for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.
6. Website Content Manager for uploading on ESIC HQRS Website.
7. Guard File.

Yours faithfully,

  
(Dr. Sanjiv Kochhar)  
Dy. Medical Commissioner (RC)  
For: **DIRECTOR GENERAL**

उप चिकित्सा आयुक्त (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

  
Dy. Medical Commissioner (RC)  
For: **DIRECTOR GENERAL**

उप चिकित्सा आयुक्त (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)



### List of Approved Pharmaceutical firms of Rate Contract No. 164

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)	Address of Approved Pharmaceutical Firm
1	164	Aculife Healthcare Pvt. Ltd.	9099069072, 079- 26839100, 9099165218 tendersales.sachana@aculife.co.in, nitantbhatt@aculife.co.in, sales.sachana@aculife.co.in, brijeshsanhvi@aculife.co.in	Commerce House V, Besides Vodafone House, Prahladnagar Corporate Road, Ahmedabad-380051, Gujarat, India.
2	164	ALPA LABORATORIES LTD	9301364017, 0731 4294567, 7415794617, tenders@alpalabs.in	33/2, A.B. Road, Pigdamber 453 446, Indore (MP)
3	164	Bajaj Healthcare Limited	9324291478, 022-66177400, 022-66177458, marketing@bajajhealth.com, shantaram@bajajhealth.com	602-606, 6th Floor, Bhoomi Velocity Infotech Park, Plot No: B-39, Road No. 23, Above ICICI Bank, Wagle Industrial Estate, Thane (W)- 400604
4	164	Bharat Serums And Vaccines Limited	9967657228, 022-45043456, 022-45043200, institution@bsvgroup.com, nitin.nagar@bsvgroup.com	3rd floor, Liberty Towers, Plot No. K-10, Behind Reliable Plaza, Kalwa Industrial Estate, Airoli, Navi Mumbai – 400708
5	164	Biodeal Pharmaceuticals Ltd.	88021 37137, 0120-6025048, 7428744221, institution1@biodealpharma.com, Institution@biodealpharma.com	Vill. Saini Majra, Nalagarh Ropar Road Nalagarh, Solan, Himachal Pradesh 174101
6	164	Brawn Laboratories Limited	8448300569, 0124-2970224, 8800275984, inst@brawnlab.in	Brawn laboratories Limited, Plot No. 44 Pace city-1, Sector-37, Gurgaon-122001 (Haryana)
7	164	Cipla Ltd.	+91 7506003699, 022 24826000, 022 24826120, +91 9506692389, Institution@Cipla.com, ketan.chaudhari@cipla.com, prashant.gupta1@cipla.com	Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, lower Parel, Mumbai- 400 013



### List of Approved Pharmaceutical firms of Rate Contract No. 164

8	164	Concord Biotech Limited	7573036632,7968138700,7968138725, 9830486374, tenderbusiness@concordbiotech.com,baijuvarghese@concordbiotech.com	1601-1602, B-Wing, Mondeal Heights, Isckon Cross Road, S G Highway, Ahmedabad 380015 Gujarat
9	164	Dr. Reddy's Laboratories Limited	9000995868 & 9154302501,040 49048400,040 49048800, 9000995868 & 9154302501 , ibtpricing@drreddys.com,ibt@drreddys.com	7-1-27, Ameerpet, Hyderabad 500016, Telangana, India
10	164	Eisai Pharmaceuticals India Pvt Ltd	9930305098,022 4075 1311, tenders@eisaiindia.com,r2-jain@eisaiindia.com	6th Floor, A Wing, Marwah Centre, Krishanlal Marwah Marg, Sakinaka, Andheri (East), Mumbai - 400072
11	164	Eris Lifesciences Limited	8884111968, 079 69661000/1001, 079 69661155,9820407013, marketaccess@erislifesciences.com	Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad - 380054
12	164	GALPHA LABORATORIES LIMITED	7718883168, 22 3040 0999, 22 3040 0900, 7718883168, kuldeep.malhotra@galphi.com,a rindam@galphi.com,sanjay.pathak@galphi.com	E 221, Kanakia Zillion Junction of LBS Marg and CST Road, BKC Annexe, Kurla West, Mumbai - 400070
13	164	Getwell Pharma India Private Limited	70651 05826,124-4477981/82,0124-4477986,70651 05826, ruchi@getwelloncology.com	474, Udyog Vihar, Phase V, Gurgaon - 122016 (Haryana)
14	164	HAB Pharmaceuticals & Research Ltd	9930212908,022-66261409, 022-66261414, marketing@habpharma.in	A-301 PENINSULA BUSINESS PARK, GANPATRAO KADAM MARG LOWER PAREL MUMBAI 400013
15	164	Hindustan Laboratories Limited	9820787558, 022-42460500, 42460526, 022-42460531, 7710055194, sales@hindlab.com,tender@hindlab.com,kunjaldedhia@hindlab.com	A-302, Victory Park, Chandavarkar Road, Borivali (West), Mumbai - 400092, Maharashtra





### List of Approved Pharmaceutical firms of Rate Contract No. 164

16	164	Intas Pharmaceuticals Ltd	9810824433, 079-39837000, 9810824433, abhishek_bajaj@intaspharma.com	Intas Pharmaceuticals Limited, Corporate House, Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad- 380054
17	164	Johnson & Johnson Pvt. Ltd.	9920277765, 022 66646464, 022 66718200, tenderspharma@its.jnj.com,RAs awale@ITS.JNJ.com	501, Arena Space, Behind Majas Bus Depot, Off. J.V. Link Road, Jogeshwari (East), Mumbai- 400060
18	164	LUPIN LIMITED	8879967909, (022) 66402969, manoj Singh4@lupin.com	3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East) , Mumbai - 400055 AND Lupin Limited,202,Agarwal Plaza,Plot No. 3, DDA Complex, Sector 14, Prashant Vihar, Rohini.New Delhi-110085
19	164	Maan Pharmaceuticals Ltd	9825070124,02762- 224642,02762 224610, info@maanpharma.com	MAAN PHARMACEUTICALS LTD., PLOT NO.1, G.I.D.C PHASE-2, MODHERA ROAD, MEHSANA-384 002
20	164	Macleods Pharmaceuticals Limited	7208993479, 2266762672, 2229256599, 7304564056, tenders@macleodspharma.com	Atlanta Arcade, Marol Church Road, Opposite Leela Hotel , Andheri (East), Mumbai – 400059
21	164	Marc Laboratories Limited	8795838376, 9389826268, 0522-2620365, institution.marclabs@gmail.com, institution.marclabs@gmail.com, amit.kishore@marclabs.in	Avanbai Mansion, 3, Vidhan Sabha Marg, Lucknow-226001(UP)
22	164	Medipol Pharmaceutical India Pvt. Ltd.	9821648300, 91-11-22380624, 91-11-22305399, medipodel@gmail.com,sales@medipol.in,instsales@medipol.in	G-52, Sector-63, Noida-201301, U.P. India

क.प्र.बी.नि.  
E S I C**List of Approved Pharmaceutical firms of Rate Contract No. 164**

23	164	MESMER PHARMACEUTICAL S	9444903427,044-22522618, tenders.mesmer@iconlife.in,gvs mani.mesmer@iconlife.in	Mesmer Pharmaceuticals, Vedha No 13, Mangala Nagar, 1st Main Road, Porur, Chennai- 600116,Tamil Nadu.
24	164	Micro Labs Ltd	9350808984, : +91-80-2237 0451-57 line, : +91-80-2237 0463 , 9350808984 ; 9591211411 , rakeshsharma_micro@yahoo.co.i n	No. 31, Race Course Road, Bangalore-560 001
25	164	MICRON PHARMACEUTICAL S	8160376623, 0260 2405400/05/07/411/412, 0260 2405419, 9820081388, contactus@micronpharma.in,sal es@micronpharma.in	PLOT NO 2117 A-2 PHASE III GIDC VAPI 396 195
26	164	Midas Care Pharmaceuticals Pvt. Ltd.	9013490294, 42193900, tender@midas- care.com,sumitkumar.nagar@mi das-care.com	Lotus Corporate Park, B Wing, 3rd Floor, Jay Coach, Graham Firth Compound, WE Highway, Goregaon (East), Mumbai 400 063
27	164	Morepen Laboratories Limited	8368339016, 0124 - 4892000, 0124 - 4892000,8368339016, 9891759817, 9716878148, yadvinder.singh@morepen.com,i nstitution@morepen.com	2nd Floor, Tower - C, DLF Cyber Park, Udyog Vihar - III, Sector - 20, Gurugram - 122016 (Haryana)
28	164	MSN Laboratories Private Limited	7331135495,040 30438716, 040 30438798, tenders@msnlabs.com	MSN House, Plot No. C- 24, Industrial Estate, Sanathnagar, Hyderabad- 500018,Telangana
29	164	Overseas Health Care Private Limited	9872019733, 01826-222886, 01826-222885, info@overseashealthcare.co.in,d mohcpl@gmail.com	OVERSEAS HEALTHCARE PRIVATE LIMITED, 335KM Milestone, National Highway No.1, P.O. Box 25, Phillaur-144410, District Jalandhar, Punjab State
30	164	Primus Pharmaceuticals	9034004055, tenders@primuspharmaceutical. com,marketing@primuspharmac eutical.com	Primus Pharmaceuticals, Sadhoura Road, Mouza Ogli Khari, Vill. Asgarpur Majra, Distt. Sirmour ,173030, H.P



### List of Approved Pharmaceutical firms of Rate Contract No. 164

31	164	RIVPRA FORMULATION PVT. LTD	9818879555, 9311789536, (0120-4277177), tender@rivpraformulation.com,info@rivpraformulation.com	RIVPRA FORMULATION PVT. LTD. CORPORATE OFFICE: RADISSON BLU, KM TRADE TOWER, 11TH FLOOR, OFFICE NO: 1008, H-3, KAUSHAMBI, GHAZIABAD-201010 (U.P)
32	164	Samarth Life Sciences Pvt. Ltd.	8591082841, Tel No. - 022-2871 9322, 28719501, 2871 9510, 9967472793, samarth.tenders@samarthlife.com,rajive.shrivastava@samarthlife.com,samarth.tenders@samarthlife.com	Samarth Life Sciences Pvt. Ltd. Samarth House, 168, Bangur Nagar, Off Link Road, Near Ayappa Temple & Kallol Kali Temple Goregaon (West), Mumbai - 400 090 India
33	164	SIGNATURE PHYTOCHEMICAL INDUSTRIES	9930212908, 022-66261428,022-66261414, marketing@signaturepi.in	Signature Phytochemical Industries, 323,3rd Floor T.V Industrial Estate S.K Ahire Marg Worli Mumbai 4000 30 Maharashtra
34	164	STANEX DRUGS AND CHEMICALS PRIVATE LIMITED	9000844323, institution@stanexdnc.com,kbr@stanexdnc.com	16-140/1, prashanti nagar, street no 3, uppall hyderabad 500039
35	164	Sun Pharma Laboratories Limited	9820439962,022 4324 4324, 022 4324 4343, Thomas.Edakalathoor@sunpharma.com	Sun House, 201 B/1, Western Express Highway, Goregaon East, Mumbai - 400063
36	164	Theon Pharmaceuticals Limited	7696000688, 0172-5210200, 0172-5033851, tender@theonpharma.com,spsingh@theonpharma.com	Plot no. 400, Industrial Area, Phase-1, Panchkula-134113
37	164	Torrent Pharmaceuticals Ltd	7069000578, 079 26599551,079 26582100,7069000550 , 578 , 509 , 559, hemantameher@torrentpharma.com,vikrampatel@torrentpharma.com,jaydabhi@torrentpharma.com,bijendrakumarsharma@torrentian.com,hadmatkhatik@torrentpharma.com	Torrent Pharmaceuticals Ltd, Torrent House, Off Ashram Road, Ahmedabad-380009



**List of Approved Pharmaceutical firms of Rate Contract No. 164**

38	164	TROIKAA PHARMACEUTICALS LIMITED	9879615617, 079 26856242, 079 26856246, 7227069020, tenderorder@troikaapharma.co m,institution@troikaapharma.co m	TROIKAA HOUSE -1, SATYA MARG, BODAKDEV, AHMEDABAD - 380054
39	164	UNICURE INDIA LTD	9910676844, 0120- 4786713,0120-4320184, 9810337912, unicure@unicureindia.com,mku mar712@gmail.com	C-21, 22 & 23, Sector-3, Noida-201301, distt. Gautam Budh Nagar (U.P.)
40	164	Venus Remedies Limited	9316311007, 0172-2933090-94, 0172-2565566 , 9876999297, imd_staff1@venusremedies.com ,imd_staff2@venusremedies.co m,imd_staff3@venusremedies.c om,institution@venusremedies.c om	Plot no – 51-52, Industrial Area, Phase – I, Panchkula, Haryana - 134113
41	164	Wallace Pharmaceuticals Pvt. Ltd.	9820360019 / 9811129701, 022- 68311100, 022-28390733, pravinwani@wallacepharma.net,i nstitution@wallacepharma.net,pr avinwani@wallacepharma.net,in stitution@wallacepharma.net,ms 379@hotmail.com	Wallace Towers,5th Floor,139-140/B/1, Western Express Highway, Vile Parle(E),Mumbai-400057  Mktg Office: A 303/312 Floral Deck Plaza, Off Central MIDC Road, Andheri (East), Mumbai- 400093
42	164	ZIM LABORATORIES LIMITED	9818678219,7122981960,71182 71470, tendercell@zimlab.in,admin01@z imlab.in,marketing@zimlab.in	Saddoday Gyan (Ground Floor), Opp. NADT Nelson Square, Nagpur-440013 (MS)



**Index RC- 164**

S.No.	RC No.	Item No.	Item Name and Description
1	164	NLEM003	Mesalamine/ Mesalazine Tablet- Each Tab to contain: Mesalamine/ Mesalazine 400mg.
2	164	NLEM007	Abacavir Tablet: Each Tablet to contain: Abacavir 300 mg
3	164	NLEM015	Albendazole Chewable Tablet-Each Chewable Tablet to contain Albendazole 400mg
4	164	NLEM019	Amitriptyline Tab- Each Tablet to contain: Amitriptyline 50mg
5	164	NLEM020	Amitriptyline Tab- Each Tablet to contain: Amitriptyline 75mg
6	164	NLEM021	Amlodipine Tab- Each Tablet to contain: Amlodipine 10mg
7	164	NLEM022	Amlodipine Tab- Each Tablet to contain: Amlodipine 2.5 mg
8	164	NLEM036	Ascorbic acid (Vitamin C) Tablet - Each Tablet to contain Ascorbic Acid 100mg
9	164	NLEM038	Atorvastatin 40 mg Tab - Each tablet to contain: Atorvastatin 40 mg
10	164	NLEM039	Atorvastatin 80 mg Tab - Each tablet to contain: Atorvastatin 80 mg
11	164	NLEM042	Azithromycin Tab. - Each Tablet to contain: Azithromycin 1000mg
12	164	NLEM044	Baclofen Tab- Each Tablet to contain: Baclofen 5 mg
13	164	NLEM052	Bortezomib Inj- Each Vial to contain: Bortezomib 2 mg Packing: 1 Vial
14	164	NLEM053	Metered Dose Inhaler - Each dose to contain: Formoterol 6 mcg, Budesonide 100 mcg ,Packing:Equal to or more than 120 MDI
15	164	NLEM054	Metered Dose Inhaler - Each dose to contain: Formoterol 6 mcg, Budesonide 400 mcg, Packing:Equal to or more than 120 MDI



ESIC

16	164	NLEM055	Budesonide Inhaler- Each Metered Dose to contain : Budesonide 200 mcg Packing:Equal to or more than 120 MDI
17	164	NLEM057	Budesonide Respirator solution for use in nebulizer: Each ml to contain Budesonide 0.5 mg Packing:2ml Respule
18	164	NLEM058	Budesonide Respirator solution for use in nebulizer: Each ml to contain Budesonide 1 mg Packing:2ml Respule
19	164	NLEM060	Buprenorphine and Naloxone Tablet-Each Sub-lingual Tablet contain Buprenorphine 0.4 mg and Naloxone 0.1 mg.
20	164	NLEM061	Buprenorphine and Naloxone Tablet-Each Sub-lingual Tablet contain Buprenorphine 2 mg and Naloxone 0.5 mg
21	164	NLEM062	Buprenorphine Tablet-Each Sub-lingual Tablet contain Buprenorphine 0.4 mg
22	164	NLEM065	Calcium Carbonate Tablet- Each Tablet to contain Calcium Carbonate 1250 mg (equivalent to elemental Calcium 500 mg)
23	164	NLEM072	Carbimazole Tab- Each Tab to contain: Carbimazole 10 mg.
24	164	NLEM073	Carbimazole Tab- Each Tab to contain: Carbimazole 20 mg.
25	164	NLEM074	Carboxy Methyl Cellulose Eye Drop- Each ml to contain: Carboxy Methyl Cellulose 10mg Packing: 10 ml Vial
26	164	NLEM079	Cefixime Oral Liquid - Each 5ml to contain: Cefixime 100mg, Packing:30ml Bottle
27	164	NLEM080	Cefixime Tab. - Each Tablet to Contain: Cefixime 400mg
28	164	NLEM081	Ceftriaxone Inj. - Each vial to contain: Ceftriaxone 2000mg Packing: 1 Vial
29	164	NLEM090	Clarithromycin Tab- Each Tab to contain: Clarithromycin 250mg
30	164	NLEM092	Clindamycin Cap- Each Capsule to contain: Clindamycin 150mg

क.रा.बी.नि.  
ESIC

31	164	NLEM098	Clonazepam Tab - Each Tab to contain: Clonazepam 0.25mg
32	164	NLEM099	Clopidogrel Tab- Each Tab to contain: Clopidogrel 150mg
33	164	NLEM100	Clotrimazole Lotion- contain Clotrimazole 1 % Packing: 15ml vial
34	164	NLEM107	Clozapine Tab: Each Tab to contain: Clozapine 50mg
35	164	NLEM124	Darunavir Tab- Each Tablet to contain: Darunavir 600mg
36	164	NLEM132	Dicyclomine Inj. - Each ml to contain: Dicyclomine 10 mg Packing: 2ml Vial/Amp
37	164	NLEM140	Donepezil Tab-Each Tablet contain:Donepezil 5mg
38	164	NLEM144	Efavirenz Tab- Each Tab to contain:Efavirenz 600mg
39	164	NLEM145	Enoxaparin Injection- Each PFS to contain Enoxaparin 40 mg / 0.4 ml. Packing: 0.4ml PFS
40	164	NLEM147	Escitalopram Tab- Each Tab to contain: Escitalopram 5mg
41	164	NLEM153	Ferrous Salt and Folic acid Oral liquid- Each ml to contain 20 mg elemental iron and 100mcg Folic acid., Packing:15 ml bottle
42	164	NLEM154	Ferrous Salt and Folic acid Tab- Each tablet to contain 100 mg elemental iron and 500mcg Folic acid.
43	164	NLEM159	Fluconazole tab - Each tab to contain : Fluconazole 200 mg.
44	164	NLEM160	Fluconazole tab - Each tab to contain : Fluconazole 400 mg.
45	164	NLEM161	Fluconazole tab - Each tab to contain : Fluconazole 50 mg.
46	164	NLEM165	Fluoxetine Cap- Each Cap to contain: Fluoxetine 10mg
47	164	NLEM166	Fluoxetine Cap- Each Cap to contain: Fluoxetine 40mg
48	164	NLEM167	Fluoxetine Cap- Each Cap to contain: Fluoxetine 60mg

क.रा.बी.वि.  
ESIC

49	164	NLEM172	Gentamycin Inj. - Each ml to contain: Gentamycin 10mg Packing: 2ml Vial
50	164	NLEM175	Glyceryl trinitrate Sublingual Tablet-Each tablet to contain Glyceryl trinitrate 0.5 mg
51	164	NLEM185	Heparin Inj- Each ml to contain: Heparin 1000 IU Packing: 5ml Vial/Amp
52	164	NLEM192	Hydroxy Chloroquine Tab- Each Tab to contain: Hydroxy Chloroquine 400mg
53	164	NLEM199	Itraconazole Cap- Each Cap to contain: Itraconazole 200mg
54	164	NLEM207	Leuprolide Inj- Each Vial to contain: Leuprolide Acetate 11.25mg Packing: 1 Vial
55	164	NLEM208	Leuprolide Inj- Each Vial to contain: Leuprolide Acetate 22.5mg Packing: 1 Vial
56	164	NLEM209	Levetiracetam Tab-Each Modified release Tablet to contain Levetiracetam 750mg
57	164	NLEM210	Levetiracetam Tab- Each Tab to contain: Levetiracetam 750mg
58	164	NLEM215	Levofloxacin Tab - Each Tablet to contain: Levofloxacin 750 mg.
59	164	NLEM217	Lignocaine Inj- Lignocaine 1% Packing: 50ml bottle
60	164	NLEM225	Lopinavir + Ritonavir Tab-Each Tab to contain:Lopinavir 200 mg and Ritonavir 50 mg
61	164	NLEM238	Metformin Tablet-Each tablet to contain Metformin 1000mg
62	164	NLEM244	Metoprolol Tablet: Each Tablet to contain Metoprolol 25 mg
63	164	NLEM245	Metoprolol Modified Release Tab- Each Tab to contain: Metoprolol 100mg
64	164	NLEM246	Metoprolol Tab-Each Tab to contain: Metoprolol 100mg
65	164	NLEM252	Montelukast Tab- Each Tab to contain: Montelukast 4mg
66	164	NLEM254	Montelukast Tab- Each Tab to contain: Montelukast 5mg



भारत सरकार  
E S I C

67	164	NLEM255	Moxifloxacin Tab- Each Tab to contain: Moxifloxacin 400mg
68	164	NLEM256	Mycophenolate Mofetil Tab- Each Tab to contain: Mycophenolate Mofetil 250mg
69	164	NLEM263	Nicotine Tab- Each Chewable Tab to contain:Nicotine 2mg
70	164	NLEM269	Omeprazole Capsule - Each Cap to contain:Omeprazole 10 mg
71	164	NLEM270	Omeprazole Capsule - Each Cap to contain:Omeprazole 40 mg
72	164	NLEM271	Omeprazole Powder for oral liquid: Each sachet to contain Omeprazole 20 mg
73	164	NLEM278	Permethrin Lotion- Permethrin 1%, Packing: 60ml Bottle
74	164	NLEM290	Piperacillin +Tazobactam Powder for Injection- Each vial to contain: Piperacillin 1000mg+Tazobactam 125mg Packing: 1 Vial
75	164	NLEM291	Piperacillin +Tazobactam Powder for Injection- Each vial to contain: Piperacillin 2000mg+Tazobactam 250mg Packing: 1 Vial
76	164	NLEM307	Pyrazinamide Tab- Each Tab to contain: Pyrazinamide 1000mg
77	164	NLEM308	Pyrazinamide Tab- Each Tab to contain: Pyrazinamide 1500mg
78	164	NLEM311	Pyridoxine Tab- Each Tab to contain: Pyridoxin 100mg
79	164	NLEM315	Risperidone Inj (Long acting)- Each Amp to contain: Risperidone 25 mg Packing: 1 Vial/Amp
80	164	NLEM316	Risperidone Inj(Long acting)- Each Amp to contain: Risperidone 37.5 mg Packing: 1 Vial/Amp
81	164	NLEM318	Risperidone Tab- Each Tab to contain: Resperidone 4mg
82	164	NLEM320	Salbutamol Oral liquid-Each 5ml to contain:Salbutamol 2 mg, Packing:100ml bottle
83	164	NLEM322	Salbutamol Tab- Each Tab to contain:Salbutamol 4 mg



ए.एस.आई.सी.  
E S I C

84	164	NLEM329	Sodium Valproate Modified Release Tab- Each Tab to contain: Sodium Valproate 300mg
85	164	NLEM330	Sodium Valproate Tab- Each Tab to contain: Sodium Valproate 500mg.
86	164	NLEM336	Telmisartan Tab- Each Tab to contain: Telmisartan 80mg
87	164	NLEM339	Tenofovir + Lamivudine + Efavirenz Tab- Each Tab to contain:Tenofovir Disproxil Fumarate 300mg, Lamivudine 300mg,Efavirenz 600 mg
88	164	NLEM340	Tenofovir Disproxil Fumarate + Lamivudine +Dolutegravir Tablet- Each Tab to contain:Tenofovir Disproxil Fumarate 300 mg, Lamivudine 300 mg, Dolutegravir 50 mg
89	164	NLEM342	Tenofovir Tab- Each Tab to contain Tenofovir Disproxil Fumarate 300 mg
90	164	NLEM347	Tramadol Cap- Each Cap to contain:Tramadol 100 mg
91	164	NLEM351	Vancomycin Inj- Each Vial to contain: Vancomycin 1000mg Packing: 1 Vial
92	164	NLEM353	Vecuronium Inj- Each Vial to contain: Vecuronium 10mg Packing: 1 Vial
93	164	NLEM359	Warfarin Tab- Each Tab contain: Warfarin 1mg
94	164	NLEM360	Warfarin Tab- Each Tab contain: Warfarin 5mg
95	164	NLEM361	Xylometazoline Nasal drops- Contain Xylometazoline 0.05% Packing: 10ml Vial

DG-ESIC Central Rate Contract No. 164 valid w.e.f. 08.04.2025 to 07.04.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Sun Pharma Laboratories Limited	NLEM003	Mesalamine/ Mesalazine Tablet- Each Tab to contain: Mesalamine/ Mesalazine 400mg.	1 Tab	Mesacol Tab	Strip of 15's	5.28/ 1 Tab	Rupees Five Paise TwentyEight Only	L1
164	MICRON PHARMACEUTICALS	NLEM007	Abacavir Tablet: Each Tablet to contain: Abacavir 300 mg	1 Tab	Same as in Item	10 Tab	14.40/ 1 Tab	Rupees Fourteen Paise Fourty Only	L1
164	ZIM LABORATORIES LIMITED	NLEM015	Albendazole Chewable Tablet- Each Chewable Tablet to contain Albendazole 400mg	1 Tab	Same as in Item	10 Tab	1.17/ 1 Tab	Rupee One Paise Seventeen Only	L1
164	Bajaj Healthcare Limited	NLEM015	Albendazole Chewable Tablet- Each Chewable Tablet to contain Albendazole 400mg	1 Tab	Same as in Item	Blister of 10x1 Tablet	1.35/ 1 Tab	Rupee One Paise ThirtyFive Only	L2
164	SIGNATURE PHYTOCHEMICAL INDUSTRIES	NLEM015	Albendazole Chewable Tablet- Each Chewable Tablet to contain Albendazole 400mg	1 Tab	ALDOL -400	10s	1.35/ 1 Tab	Rupee One Paise ThirtyFive Only	L2
164	MESMER PHARMACEUTICALS	NLEM019	Amitriptyline Tab- Each Tablet to contain: Amitriptyline 50mg	1 Tab	AMICON 50	Strip of 10 Tabs	0.68/ 1 Tab	Paise SixtyEight Only	L1
164	MESMER PHARMACEUTICALS	NLEM020	Amitriptyline Tab- Each Tablet to contain: Amitriptyline 75mg	1 Tab	AMICON 75	Strip of 10 Tabs	0.78/ 1 Tab	Paise SeventyEight Only	L1
164	Cipla Ltd.	NLEM021	Amlodipine Tab- Each Tablet to contain: Amlodipine 10mg	1 Tab	AMLOPRES - 10	Strip of 10's Tabs	0.29/ 1 Tab	Paise TwentyNine Only	L1

  
 उप-पिकेत्ता आर्यवक्त (आर.सी./पी.सी.)  
 Deputy Medical Commissioner (RC/PC)

DG-ESIC Central Rate Contract No. 164 valid w.e.f. 08.04.2025 to 07.04.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Micro Labs Ltd	NLEM021	Amlodipine Tab- Each Tablet to contain: Amlodipine 10mg	1 Tab	AMLONG 10	15's Tabs	0.59/ 1 Tab	Paise FiftyNine Only	L2
164	ALPA LABORATORIES LTD	NLEM021	Amlodipine Tab- Each Tablet to contain: Amlodipine 10mg	1 Tab	Same as in Item	14 Tab	0.66/ 1 Tab	Paise SixtySix Only	L3
164	Cipla Ltd.	NLEM022	Amlodipine Tab- Each Tablet to contain: Amlodipine 2.5 mg	1 Tab	AMLOPRES-2.5	Strip of 15's Tabs	0.17/ 1 Tab	Paise Seventeen Only	L1
164	Micro Labs Ltd	NLEM022	Amlodipine Tab- Each Tablet to contain: Amlodipine 2.5 mg	1 Tab	AMLONG 2.5	15's Tabs	0.46/ 1 Tab	Paise FourtySix Only	L2
164	Macleods Pharmaceuticals Limited	NLEM022	Amlodipine Tab- Each Tablet to contain: Amlodipine 2.5 mg	1 Tab	AMLOVAS 2.5	Strip of 15 Tabs	0.73/ 1 Tab	Paise SeventyThree Only	L3
164	MICRON PHARMACEUTICALS	NLEM036	Ascorbic acid (Vitamin C) Tablet - Each Tablet to contain Ascorbic Acid 100mg	1 Tab	Same as in Item	10 Tab	0.22/ 1 Tab	Paise TwentyTwo Only	L1
164	Eris Lifesciences Limited	NLEM038	Atorvastatin 40 mg Tab - Each tablet to contain: Atorvastatin 40 mg	1 Tab	ATORSAVE 40	15'S Strip	1.03/ 1 Tab	Rupee One Paise Three Only	L1
164	SIGNATURE PHYTOCHEMICAL INDUSTRIES	NLEM038	Atorvastatin 40 mg Tab - Each tablet to contain: Atorvastatin 40 mg	1 Tab	TORVATIN-40	10s	1.04/ 1 Tab	Rupee One Paise Four Only	L2
164	Micro Labs Ltd	NLEM038	Atorvastatin 40 mg Tab - Each tablet to contain: Atorvastatin 40 mg	1 Tab	ASTIN-40	10's Tabs	1.18/ 1 Tab	Rupee One Paise Eighteen Only	L3

DG-ESIC Central Rate Contract No. 164 valid w.e.f. 08.04.2025 to 07.04.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Eris Lifesciences Limited	NLEM039	Atorvastatin 80 mg Tab - Each tablet to contain: Atorvastatin 80 mg	1 Tab	ATORSAVE 80	15'S Strip	1.65/ 1 Tab	Rupee One Paise SixtyFive Only	L1
164	Micro Labs Ltd	NLEM039	Atorvastatin 80 mg Tab - Each tablet to contain: Atorvastatin 80 mg	1 Tab	ASTIN-80	10's Tabs	2.80/ 1 Tab	Rupees Two Paise Eighty Only	L2
164	Cipla Ltd.	NLEM039	Atorvastatin 80 mg Tab - Each tablet to contain: Atorvastatin 80 mg	1 Tab	ATORLIP - 80	Strip of 10's Tabs	2.88/ 1 Tab	Rupees Two Paise EightyEight Only	L3
164	Hindustan Laboratories Limited	NLEM042	Azithromycin Tab. - Each Tablet to contain: Azithromycin 1000mg	1 Tab	HIZITHROMYCIN	10 Tablets Strip	25.00/ 1 Tab	Rupees TwentyFive Only	L1
164	MESMER PHARMACEUTICALS	NLEM044	Baclofen Tab- Each Tablet to contain: Baclofen 5 mg	1 Tab	BACFEN 5	Strip of 10 Tabs	0.48/ 1 Tab	Paise FourtyEight Only	L1
164	Samarth Life Sciences Pvt. Ltd.	NLEM052	Bortezomib Inj- Each Vial to contain: Bortezomib 2 mg Packing:1 Vial	1 vial	BORTESAM	1 VIAL	232.20/ 1 vial	Rupees Two Hundred ThirtyTwo Paise Twenty Only	L1
164	Getwell Pharma India Private Limited	NLEM052	Bortezomib Inj- Each Vial to contain: Bortezomib 2 mg Packing:1 Vial	1 vial	Neomib	1 Vial	2603.25/ 1 vial	Rupees Two Thousand Six Hundred Three Paise TwentyFive Only	L2

  
 उप चिकित्सा आकुरु (आर.सी./पी.सी.)  
 Deputy Medical Commissioner (RC/PC)

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Midas Care Pharmaceuticals Pvt. Ltd.	NLEM053	Metered Dose Inhaler - Each dose to contain: Formoterol 6 mcg, Budesonide 100 mcg  Packing: Equal to or more than 120 MDI	1 Metered Dose	Forb 100	120 metered dose	0.54/ 1 Metered Dose	Paise FiftyFour Only	L1
164	Cipla Ltd.	NLEM053	Metered Dose Inhaler - Each dose to contain: Formoterol 6 mcg, Budesonide 100 mcg  Packing: Equal to or more than 120 MDI	1 Metered Dose	FORACORT 100 INHALER WITH DOSE COUNTER	120 MDs	0.67/ 1 Metered Dose	Paise SixtySeven Only	L2
164	Midas Care Pharmaceuticals Pvt. Ltd.	NLEM054	Metered Dose Inhaler - Each dose to contain: Formoterol 6 mcg, Budesonide 400 mcg  Packing: Equal to or more than 120 MDI	1 Metered Dose	Forb 400	120 metered dose	0.63/ 1 Metered Dose	Paise SixtyThree Only	L1
164	Cipla Ltd.	NLEM054	Metered Dose Inhaler - Each dose to contain: Formoterol 6 mcg, Budesonide 400 mcg  Packing: Equal to or more than 120 MDI	1 Metered Dose	FORACORT 400 INHALER WITH DOSE COUNTER	120 MDs	0.70/ 1 Metered Dose	Paise Seventy Only	L2

*Sanyal*  
उप चिकित्सा आयुक्त (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Cipla Ltd.	NLEM055	Budesonide Inhaler- Each Metered Dose to contain : Budesonide 200 mcg Packing:Equal to or more than 120 MDI	1 Metered Dose	BUDECORT 200 INHALER	200 MDs	0.41/ 1 Metered Dose	Paise FourtyOne Only	L1
164	Midas Care Pharmaceuticals Pvt. Ltd.	NLEM055	Budesonide Inhaler- Each Metered Dose to contain : Budesonide 200 mcg Packing:Equal to or more than 120 MDI	1 Metered Dose	Budesone 200	200 metered dose	0.45/ 1 Metered Dose	Paise FourtyFive Only	L2
164	Cipla Ltd.	NLEM057	Budesonide Respirator solution for use in nebulizer: Each ml to contain Budesonide 0.5 mg Packing:2ml Respule	1 Respule	BUDECORT	2 ML RESPULE	2.60/ 1 Respule	Rupees Two Paise Sixty Only	L1
164	Cipla Ltd.	NLEM058	Budesonide Respirator solution for use in nebulizer: Each ml to contain Budesonide 1 mg Packing:2ml Respule	1 Respule	BUDECORT	2 ML RESPULE	4.20/ 1 Respule	Rupees Four Paise Twenty Only	L1
164	Maan Pharmaceuticals Ltd.,	NLEM060	Buprenorphine and Naloxone Tablet-Each Sub-lingual Tablet contain Buprenorphine 0.4 mg and Naloxone 0.1 mg.	1 Tab	Same as in Item	10X10 TABLETS	4.05/ 1 Tab	Rupees Four Paise Five Only	L1
164	Maan Pharmaceuticals Ltd.,	NLEM061	Buprenorphine and Naloxone Tablet-Each Sub-lingual Tablet contain Buprenorphine 2 mg and Naloxone 0.5 mg	1 Tab	Same as in Item	10X10 TABLETS	8.10/ 1 Tab	Rupees Eight Paise Ten Only	L1

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	MICRON PHARMACEUTICALS	NLEM062	Buprenorphine Tablet-Each Sublingual Tablet contain Buprenorphine 0.4 mg	1 Tab	Same as in Item	10 Tab	2.43/ 1 Tab	Rupees Two Paise FourtyThree Only	L1
164	Maan Pharmaceuticals Ltd.,	NLEM062	Buprenorphine Tablet-Each Sublingual Tablet contain Buprenorphine 0.4 mg	1 Tab	Same as in Item	10X10 TABLETS	3.60/ 1 Tab	Rupees Three Paise Sixty Only	L2
164	Hindustan Laboratories Limited	NLEM065	Calcium Carbonate Tablet- Each Tablet to contain Calcium Carbonate 1250 mg (equivalent to elemental Calcium 500 mg)	1 Tab	HICAL-500	10 Tablets Strip	1.50/ 1 Tab	Rupee One Paise Fifty Only	L1
164	GALPHA LABORATORIES LIMITED	NLEM065	Calcium Carbonate Tablet- Each Tablet to contain Calcium Carbonate 1250 mg (equivalent to elemental Calcium 500 mg)	1 Tab	Galcal 500	15TABS	1.68/ 1 Tab	Rupee One Paise SixtyEight Only	L2
164	Biodeal Pharmaceuticals Ltd.	NLEM072	Carbimazole Tab- Each Tab to contain: Carbimazole 10 mg.	1 Tab	Same as in Item	100 TAB BOTTLE	0.63/ 1 Tab	Paise SixtyThree Only	L1
164	Macleods Pharmaceuticals Limited	NLEM072	Carbimazole Tab- Each Tab to contain: Carbimazole 10 mg.	1 Tab	ANTI THYROX 10	Bottle of 100 Tabs	3.40/ 1 Tab	Rupees Three Paise Fourty Only	L2
164	Macleods Pharmaceuticals Limited	NLEM073	Carbimazole Tab- Each Tab to contain: Carbimazole 20 mg.	1 Tab	ANTI THYROX 20	Bottle of 100 Tabs	9.30/ 1 Tab	Rupees Nine Paise Thirty Only	L1

  
 Deputy Medical Commissioner (RC/PC)



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Micro Labs Ltd	NLEM074	Carboxy Methyl Cellulose Eye Drop- Each ml to contain: Carboxy Methyl Cellulose 10mg Packing: 10 ml Vial	1ml	LUBREX - DS	10ml vial	2.40/1ml	Rupees Two Paise Fourty Only	L1
164	LUPIN LIMITED	NLEM074	Carboxy Methyl Cellulose Eye Drop- Each ml to contain: Carboxy Methyl Cellulose 10mg Packing: 10 ml Vial	1ml	LACRIMOS GX	10 ML vial	2.49/1ml	Rupees Two Paise FourtyNine Only	L2
164	HAB PHARMACEUTICALS & RESEARCH LTD	NLEM074	Carboxy Methyl Cellulose Eye Drop- Each ml to contain: Carboxy Methyl Cellulose 10mg Packing: 10 ml Vial	1ml	LUBICELL -MAX	10ML Vial	2.80/1ml	Rupees Two Paise Eighty Only	L3
164	Theon Pharmaceuticals Limited	NLEM079	Cefixime Oral Liquid - Each 5ml to contain: Cefixime 100mg, Packing:30ml Bottle	1ml	Same as in Item	30ml bott	0.92/1ml	Paise NinetyTwo Only	L1
164	Macleods Pharmaceuticals Limited	NLEM079	Cefixime Oral Liquid - Each 5ml to contain: Cefixime 100mg, Packing:30ml Bottle	1ml	CEFOLAC 100	Bottle of 30ml	1.20/1ml	Rupee One Paise Twenty Only	L2
164	MICRON PHARMACEUTICALS	NLEM080	Cefixime Tab. - Each Tablet to Contain: Cefixime 400mg	1 Tab	Same as in Item	10 Tab	7.92/1 Tab	Rupees Seven Paise NinetyTwo Only	L1
164	Marc Laboratories Limited	NLEM080	Cefixime Tab. - Each Tablet to Contain: Cefixime 400mg	1 Tab	CEFOMARC-O400DT	10X10 TABS	8.54/1 Tab	Rupees Eight Paise FiftyFour Only	L2

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Theon Pharmaceuticals Limited	NLEM080	Cefixime Tab. - Each Tablet to Contain: Cefixime 400mg	1 Tab	Same as in Item	10's	10.23/ 1 Tab	Rupees Ten Paise TwentyThree Only	L3
164	Theon Pharmaceuticals Limited	NLEM081	Ceftriaxone Inj. - Each vial to contain: Ceftriaxone 2000mg Packing: 1 Vial	1vial	Same as in Item	1 Vial	34.56/ 1vial	Rupees ThirtyFour Paise FiftySix Only	L1
164	Macleods Pharmaceuticals Limited	NLEM081	Ceftriaxone Inj. - Each vial to contain: Ceftriaxone 2000mg Packing: 1 Vial	1vial	ACCUZON 2GM	1 VIAL	48.00/ 1vial	Rupees FourtyEight Only	L2
164	Morepen Laboratories Limited	NLEM090	Clarithromycin Tab- Each Tab to contain: Clarithromycin 250mg	1 Tab	KLARIM	10 Tab	6.40/ 1 Tab	Rupees Six Paise Fourty Only	L1
164	Macleods Pharmaceuticals Limited	NLEM090	Clarithromycin Tab- Each Tab to contain: Clarithromycin 250mg	1 Tab	CLARIGARD 250	Strip of 10 Tabs	7.10/ 1 Tab	Rupees Seven Paise Ten Only	L2
164	ALPA LABORATORIES LTD	NLEM092	Clindamycin Cap- Each Capsule to contain: Clindamycin 150mg	1 Cap	Same as in Item	10 Cap	6.00/ 1 Cap	Rupees Six Only	L1
164	Micro Labs Ltd	NLEM098	Clonazepam Tab - Each Tab to contain: Clonazepam 0.25mg	1 Tab	PETRIL MD 0.25	15's Tabs	0.69/ 1 Tab	Paise SixtyNine Only	L1
164	Intas Pharmaceuticals Ltd	NLEM099	Clopidogrel Tab- Each Tab to contain: Clopidogrel 150mg	1 Tab	CLAVIX 150 TAB	10 Tab	2.10/ 1 Tab	Rupees Two Paise Ten Only	L1
164	Medipol Pharmaceutical India Pvt. Ltd.	NLEM100	Clotrimazole Lotion- contain Clotrimazole 1 % Packing: 15ml vial	1ml	Same as in Item	15ml vial	1.61/1ml	Rupee One Paise SixtyOne Only	L1

  
 Deputy Medical Commissioner (RC/PC)

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	MESMER PHARMACEUTICALS	NLEM107	Clozapine Tab: Each Tab to contain: Clozapine 50mg	1 Tab	ZAPORIL 50	Strip of 10 Tabs	1.11/ 1 Tab	Rupee One Paise Eleven Only	L1
164	Intas Pharmaceuticals Ltd	NLEM107	Clozapine Tab: Each Tab to contain: Clozapine 50mg	1 Tab	SKIZORIL 50 TAB	10 Tab	1.87/ 1 Tab	Rupee One Paise EightySeven Only	L2
164	MICRON PHARMACEUTICALS	NLEM124	Darunavir Tab- Each Tablet to contain: Darunavir 600mg	1 Tab	Same as in Item	30 Tab	99.00/ 1 Tab	Rupees NinetyNine Only	L1
164	ALPA LABORATORIES LTD	NLEM132	Dicyclomine Inj. - Each ml to contain: Dicyclomine 10 mg Packing: 2ml Vial/Amp	1 Vial/Amp	Same as in Item	2ml Amp	3.88/ 1Vial/Amp	Rupees Three Paise EightyEight Only	L1
164	Biodeal Pharmaceuticals Ltd.	NLEM140	Donepezil Tab-Each Tablet contain:Donepezil 5mg	1 Tab	Same as in Item	10X10 BLISTER	0.77/ 1 Tab	Paise SeventySeven Only	L1
164	Eisai Pharmaceuticals India Pvt Ltd	NLEM140	Donepezil Tab-Each Tablet contain:Donepezil 5mg	1 Tab	Aricep	10 Tab	4.00/ 1 Tab	Rupees Four Only	L2
164	Intas Pharmaceuticals Ltd	NLEM140	Donepezil Tab-Each Tablet contain:Donepezil 5mg	1 Tab	ALZIL-5 TAB	10 Tab	4.36/ 1 Tab	Rupees Four Paise ThirtySix Only	L3
164	Cipla Ltd.	NLEM144	Efavirenz Tab- Each Tab to contain:Efavirenz 600mg	1 Tab	EFAVIR 600	30's Tabs	11.00/ 1 Tab	Rupees Eleven Only	L1
164	Venus Remedies Limited	NLEM145	Enoxaparin Injection- Each PFS to contain Enoxaparin 40 mg / 0.4 ml. Packing: 0.4ml PFS	1 PFS	COGUPERIN	PFS	86.90/ 1 PFS	Rupees EightySix Paise Ninety Only	L1

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Brawn Laboratories Limited	NLEM145	Enoxaparin Injection- Each PFS to contain Enoxaparin 40 mg / 0.4 ml. Packing: 0.4ml PFS	1 PFS	Bruparin 40	1 PFS	93.00/ 1 PFS	Rupees NinetyThree Only	L2
164	Samarth Life Sciences Pvt. Ltd.	NLEM145	Enoxaparin Injection- Each PFS to contain Enoxaparin 40 mg / 0.4 ml. Packing: 0.4ml PFS	1 PFS	LOWCAP	1 PFS	100.08/ 1 PFS	Rupees One Hundred Paise Eight Only	L3
164	MESMER PHARMACEUTICAL S	NLEM147	Escitalopram Tab- Each Tab to contain: Escitalopram 5mg	1 Tab	ESCIPRA 5	Strip of 10 Tabs	0.53/ 1 Tab	Paise FiftyThree Only	L1
164	Intas Pharmaceuticals Ltd	NLEM147	Escitalopram Tab- Each Tab to contain: Escitalopram 5mg	1 Tab	REXIPRA-5 TAB	10 Tab	1.81/ 1 Tab	Rupee One Paise EightyOne Only	L2
164	GALPHA LABORATORIES LIMITED	NLEM153	Ferrous Salt and Folic acid Oral liquid- Each ml to contain 20 mg elemental iron and 100mcg Folic acid., Packing:15 ml bottle	1ml	Same as in Item	15 ml bottle	1.12/1ml	Rupee One Paise Twelve Only	L1
164	Hindustan Laboratories Limited	NLEM154	Ferrous Salt and Folic acid Tab- Each tablet to contain 100 mg elemental iron and 500mcg Folic acid.	1 Tab	FEROHIL-100	10 Tablets Strip	0.27/ 1 Tab	Paise TwentySeven Only	L1
164	Cipla Ltd.	NLEM159	Fluconazole tab - Each tab to contain : Fluconazole 200 mg.	1 Tab	FORCAN 200	Strip of 4's Tabs	3.18/ 1 Tab	Rupees Three Paise Eighteen Only	L1
164	SIGNATURE PHYTOCHEMICAL INDUSTRIES	NLEM159	Fluconazole tab - Each tab to contain : Fluconazole 200 mg.	1 Tab	FUNGICYTE - 200	1 tab	3.80/ 1 Tab	Rupees Three Paise Eighty Only	L2

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	SIGNATURE PHYTOCHEMICAL INDUSTRIES	NLEM160	Fluconazole tab - Each tab to contain : Fluconazole 400 mg.	1 Tab	FUNGICYTE - 400	1 tab	6.42/ 1 Tab	Rupees Six Paise FourtyTwo Only	L1
164	Cipla Ltd.	NLEM161	Fluconazole tab - Each tab to contain : Fluconazole 50 mg.	1 Tab	FORCAN 50	Strip of 4's Tabs	2.75/ 1 Tab	Rupees Two Paise SeventyFive Only	L1
164	Intas Pharmaceuticals Ltd	NLEM165	Fluoxetine Cap- Each Cap to contain: Fluoxetine 10mg	1 Cap	FLUNIL 10 CAP	10 Cap	1.20/ 1 Cap	Rupee One Paise Twenty Only	L1
164	Intas Pharmaceuticals Ltd	NLEM166	Fluoxetine Cap- Each Cap to contain: Fluoxetine 40mg	1 Cap	FLUNIL 40 CAP	10 Cap	2.34/ 1 Cap	Rupees Two Paise ThirtyFour Only	L1
164	Intas Pharmaceuticals Ltd	NLEM167	Fluoxetine Cap- Each Cap to contain: Fluoxetine 60mg	1 Cap	FLUNIL 60 CAP	10 Cap	4.00/ 1 Cap	Rupees Four Only	L1
164	ALPA LABORATORIES LTD	NLEM172	Gentamycin Inj. - Each ml to contain: Gentamycin 10mg Packing: 2ml Vial	1 vial	Same as in Item	2ml Vial	4.80/ 1 vial	Rupees Four Paise Eighty Only	L1
164	TROIKAA PHARMACEUTICALS LIMITED	NLEM175	Glyceryl trinitrate Sublingual Tablet-Each tablet to contain Glyceryl trinitrate 0.5 mg	1 Tab	MYONIT INSTA	5X30 Tab	0.96/ 1 Tab	Paise NinetySix Only	L1
164	STANEX DRUGS AND CHEMICALS PRIVATE LIMITED	NLEM185	Heparin Inj- Each ml to contain: Heparin 1000 IU Packing: 5ml Vial/Amp	1 Vial/Amp	Stanhep-5	1 vial/amp	29.60/ 1Vial/Amp	Rupees TwentyNine Paise Sixty Only	L1
164	Samarth Life Sciences Pvt. Ltd.	NLEM185	Heparin Inj- Each ml to contain: Heparin 1000 IU Packing: 5ml Vial/Amp	1 Vial/Amp	CAPRIN	SML VIAL	36.09/ 1Vial/Amp	Rupees ThirtySix Paise Nine Only	L2

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Aculife Healthcare Pvt. Ltd.	NLEM185	Heparin Inj- Each ml to contain: Heparin 1000 IU Packing: 5ml Vial/Amp	1 Vial/Amp	Heparin	1 Vial/Amp	46.75/ 1Vial/Amp	Rupees FortySix Paise SeventyFive Only	L3
164	Overseas Health Care Private Limited	NLEM192	Hydroxy Chloroquine Tab- Each Tab to contain: Hydroxy Chloroquine 400mg	1 Tab	CARTIQUIN 400	10 Strips of 10 Tablets Each	4.41/ 1 Tab	Rupees Four Paise FourtyOne Only	L1
164	Wallace Pharmaceuticals Pvt. Ltd.	NLEM192	Hydroxy Chloroquine Tab- Each Tab to contain: Hydroxy Chloroquine 400mg	1 Tab	OXCQ 400	10 TAB/STRIP	5.70/ 1 Tab	Rupees Five Paise Seventy Only	L2
164	Biodeal Pharmaceuticals Ltd.	NLEM199	Itraconazole Cap- Each Cap to contain: Itraconazole 200mg	1 Cap	Same as in Item	10X10 BLISTER	2.77/ 1 Cap	Rupees Two Paise SeventySeven Only	L1
164	Macleods Pharmaceuticals Limited	NLEM199	Itraconazole Cap- Each Cap to contain: Itraconazole 200mg	1 Cap	IT-MAC 200	Strip of 10 Caps	3.60/ 1 Cap	Rupees Three Paise Sixty Only	L2
164	Primus Pharmaceuticals	NLEM199	Itraconazole Cap- Each Cap to contain: Itraconazole 200mg	1 Cap	KB-ITRA 200	10 cap	3.69/ 1 Cap	Rupees Three Paise SixtyNine Only	L3
164	Bharat Serums And Vaccines Limited	NLEM207	Leuprolide Inj- Each Vial to contain: Leuprolide Acetate 11.25mg Packing: 1 Vial	1 Vial	LUPRODEX 11.25	1 Vial	4400.00/ 1 vial	Rupees Four Thousand Four Hundred Only	L1
164	Bharat Serums And Vaccines Limited	NLEM208	Leuprolide Inj- Each Vial to contain: Leuprolide Acetate 22.5mg Packing: 1 Vial	1 Vial	LUPRODEX 22.5	1 Vial	6700.00/ 1 vial	Rupees Six Thousand Seven Hundred Only	L1

*Saini*  
रूप चिकित्सा आधिकारिक (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Intas Pharmaceuticals Ltd	NLEM209	Levetiracetam Tab-Each Modified release Tablet to contain Levetiracetam 750mg	1 Tab	LEVERA XR 750	10 Tab	4.70/ 1 Tab	Rupees Four Paise Seventy Only	L1
164	LUPIN LIMITED	NLEM209	Levetiracetam Tab-Each Modified release Tablet to contain Levetiracetam 750mg	1 Tab	EPILIVE ER 750	10 Tab	8.90/ 1 Tab	Rupees Eight Paise Ninety Only	L2
164	Intas Pharmaceuticals Ltd	NLEM210	Levetiracetam Tab-Each Tab to contain; Levetiracetam 750mg	1 Tab	LEVERA 750	10 Tab	3.70/ 1 Tab	Rupees Three Paise Seventy Only	L1
164	MSN Laboratories Private Limited	NLEM210	Levetiracetam Tab-Each Tab to contain; Levetiracetam 750mg	1 Tab	Levilex 750	Strip of 10 Tabs	3.79/ 1 Tab	Rupees Three Paise SeventyNine Only	L2
164	Cipla Ltd.	NLEM210	Levetiracetam Tab-Each Tab to contain; Levetiracetam 750mg	1 Tab	LEVEPSY 750	Strip of 10's Tabs	3.80/ 1 Tab	Rupees Three Paise Eighty Only	L3
164	Micro Labs Ltd	NLEM215	Levofloxacin Tab - Each Tablet to contain: Levofloxacin 750 mg.	1 Tab	LEVOBACT-750	10's Tabs	3.90/ 1 Tab	Rupees Three Paise Ninety Only	L1
164	RIVPRA FORMULATION PVT. LTD,	NLEM215	Levofloxacin Tab - Each Tablet to contain: Levofloxacin 750 mg.	1 Tab	LEVOMEN-750	Strips of 10 Tabs	4.55/ 1 Tab	Rupees Four Paise FiftyFive Only	L2
164	Cipla Ltd.	NLEM215	Levofloxacin Tab - Each Tablet to contain: Levofloxacin 750 mg.	1 Tab	LEVOFLOX 750	Strip of 5's Tabs	4.56/ 1 Tab	Rupees Four Paise FiftySix Only	L3
164	ALPA LABORATORIES LTD	NLEM217	Lignocaine Inj- Lignocaine 1% Packing: 50ml bottle	1ml	Same as in Item	50ml Vial	0.94/1ml	Paise NinetyFour Only	L1

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	MICRON PHARMACEUTICALS	NLEM225	Lopinavir + Ritonavir Tab-Each Tab to contain:Lopinavir 200 mg and Ritonavir 50 mg	1 Tab	Same as in Item	30 Tab	14.40/ 1 Tab	Rupees Fourteen Paise Fourty Only	L1
164	UNICURE INDIA LTD	NLEM238	Metformin Tablet-Each tablet to contain Metformin 1000mg	1 Tab	Same as in Item	Strip of 10 Tabs	0.68/ 1 Tab	Paise SixtyEight Only	L1
164	ZIM LABORATORIES LIMITED	NLEM238	Metformin Tablet-Each tablet to contain Metformin 1000mg	1 Tab	METFORZIM - 1000	10 Tab	1.21/ 1 Tab	Rupee One Paise TwentyOne Only	L2
164	Cipla Ltd.	NLEM244	Metoprolol Tablet: Each Tablet to contain Metoprolol 25 mg	1 Tab	METOLAR- 25	Strip of 15's Tabs	0.25/ 1 Tab	Paise TwentyFive Only	L1
164	Eris Lifesciences Limited	NLEM244	Metoprolol Tablet: Each Tablet to contain Metoprolol 25 mg	1 Tab	PROTOL-XL 25	10'S Strip	0.82/ 1 Tab	Paise EightyTwo Only	L2
164	Micro Labs Ltd	NLEM244	Metoprolol Tablet: Each Tablet to contain Metoprolol 25 mg	1 Tab	METAPRO-25	10's Tabs	0.90/ 1 Tab	Paise Ninety Only	L3
164	Cipla Ltd.	NLEM245	Metoprolol Modified Release Tab- Each Tab to contain: Metoprolol 100mg	1 Tab	METOLAR XR 100	Strip of 10's Caps	0.99/ 1 Tab	Paise NinetyNine Only	L1
164	Cipla Ltd.	NLEM246	Metoprolol Tab-Each Tab to contain: Metoprolol 100mg	1 Tab	METOLAR-100	Strip of 10's Tabs	0.79/ 1 Tab	Paise SeventyNine Only	L1



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Cipla Ltd.	NLEM252	Montelukast Tab- Each Tab to contain: Montelukast 4mg	1 Tab	MONTAIR 4MG	Strip of 15's Tabs	0.67/ 1 Tab	Paise SixtySeven Only	L1
164	Cipla Ltd.	NLEM254	Montelukast Tab- Each Tab to contain: Montelukast 5mg	1 Tab	MONTAIR 5MG	Strip of 15's Tabs	1.19/ 1 Tab	Rupee One Paise Nineteen Only	L1
164	Macleods Pharmaceuticals Limited	NLEM255	Moxifloxacin Tab- Each Tab to contain: Moxifloxacin 400mg	1 Tab	MOXIMAC	Strip of 10 Tabs	8.50/ 1 Tab	Rupees Eight Paise Fifty Only	L1
164	MSN Laboratories Private Limited	NLEM255	Moxifloxacin Tab- Each Tab to contain: Moxifloxacin 400mg	1 Tab	Floxsafe 400	Strip of 10 Tabs	10.48/ 1 Tab	Rupees Ten Paise FiftyEight Only	L2
164	LUPIN LIMITED	NLEM255	Moxifloxacin Tab- Each Tab to contain: Moxifloxacin 400mg	1 Tab	M CIN	5 Tab	10.89/ 1 Tab	Rupees Ten Paise EightyNine Only	L3
164	RIVPRA FORMULATION PVT. LTD,	NLEM256	Mycophenolate Mofetil Tab- Each Tab to contain: Mycophenolate Mofetil 250mg	1 Tab	MOFIMEN-250	Strips of 10 Tabs	4.60/ 1 Tab	Rupees Four Paise Sixty Only	L1
164	Concord Biotech Limited	NLEM256	Mycophenolate Mofetil Tab- Each Tab to contain: Mycophenolate Mofetil 250mg	1 Tab	Mofecon 250	10 Tabs	4.95/ 1 Tab	Rupees Four Paise NinetyFive Only	L2
164	ZIM LABORATORIES LIMITED	NLEM263	Nicotine Tab- Each Chewable Tab to contain:Nicotine 2mg	1 Tab	Same as in Item	12 Strip in one mono Carton	3.87/ 1 Tab	Rupees Three Paise EightySeven Only	L1

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Dr. Reddy's Laboratories Limited	NLEM269	Omeprazole Capsule - Each Cap to contain:Omeprazole 10 mg	1 Cap	Omez 10	15's Caps	1.22/ 1 Cap	Rupee One Paise TwentyTwo Only	L1
164	HAB PHARMACEUTICALS & RESEARCH LTD	NLEM270	Omeprazole Capsule - Each Cap to contain:Omeprazole 40 mg	1 Cap	OMCAP	10x10 caps	1.35/ 1 Cap	Rupee One Paise ThirtyFive Only	L1
164	Dr. Reddy's Laboratories Limited	NLEM270	Omeprazole Capsule - Each Cap to contain:Omeprazole 40 mg	1 Cap	Omez 40	10's Tabs	4.04/ 1 Cap	Rupees Four Paise Four Only	L2
164	Dr. Reddy's Laboratories Limited	NLEM271	Omeprazole Powder for oral liquid: Each sachet to contain Omeprazole 20 mg	1 sachet	Omez Insta	1 Sachet	8.50/ 1 sachet	Rupees Eight Paise Fifty Only	L1
164	MICRON PHARMACEUTICALS	NLEM278	Permethrin Lotion-Permethrin 1%, Packing: 60ml Bottle	1ml	Same as in Item	60ml pack	0.45/1ml	Paise FortyFive Only	L1
164	Marc Laboratories Limited	NLEM290	Piperacillin +Tazobactam Powder for Injection- Each vial to contain: Piperacillin 1000mg+Tazobactam 125mg Packing: 1 Vial	1 vial	TZACTUM 1.125gm	1 Vial	24.00/ 1 vial	Rupees TwentyFour Only	L1
164	Macleods Pharmaceuticals Limited	NLEM290	Piperacillin +Tazobactam Powder for Injection- Each vial to contain: Piperacillin 1000mg+Tazobactam 125mg Packing: 1 Vial	1 vial	TAZOMAC PS	1 VIAL	34.00/ 1 vial	Rupees ThirtyFour Only	L2

  
 उप चिकित्सा आयुक्त (आर.सी./पी.सी.)  
 Deputy Medical Commissioner (RC/PC)

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Marc Laboratories Limited	NLEM291	Piperacillin +Tazobactam Powder for Injection- Each vial to contain: Piperacillin 2000mg+Tazobactam 250mg Packing: 1 Vial	1 vial	TZACTUM 2.250gm	1 Vial	38.80/ 1 vial	Rupees ThirtyEight Paise Eighty Only	L1
164	Maan Pharmaceuticals Ltd.,	NLEM291	Piperacillin +Tazobactam Powder for Injection- Each vial to contain: Piperacillin 2000mg+Tazobactam 250mg Packing: 1 Vial	1 vial	Same as in Item	1 Vial	45.00/ 1 vial	Rupees FortyFive Only	L2
164	Macleods Pharmaceuticals Limited	NLEM291	Piperacillin +Tazobactam Powder for Injection- Each vial to contain: Piperacillin 2000mg+Tazobactam 250mg Packing: 1 Vial	1 vial	TAZOMAC	1 VIAL	45.00/ 1 vial	Rupees FortyFive Only	L2
164	Macleods Pharmaceuticals Limited	NLEM307	Pyrazinamide Tab- Each Tab to contain: Pyrazinamide 1000mg	1 Tab	MACROZIDE 1000	Strip of 6 Tabs	7.57/ 1 Tab	Rupees Seven Paise FiftySeven Only	L1
164	Macleods Pharmaceuticals Limited	NLEM308	Pyrazinamide Tab- Each Tab to contain: Pyrazinamide 1500mg	1 Tab	MACROZIDE 1500	Strip of 6 Tabs	8.50/ 1 Tab	Rupees Eight Paise Fifty Only	L1
164	Torrent Pharmaceuticals Ltd,Ahmedabad	NLEM311	Pyridoxine Tab- Each Tab to contain: Pyridoxin 100mg	1 Tab	B LONG	30 Tabs	1.25/ 1 Tab	Rupee One Paise TwentyFive Only	L1

ESIC

उप चिकित्सा आयुक्त (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Johnson & Johnson Pvt. Ltd.	NLEM315	Risperidone Inj (Long acting)- Each Amp to contain: Risperidone 25 mg Packing: 1 Vial/Amp	1 Vial/Amp	Risperdal Consta® 25 mg  Mfg.By:M/s. Cilag AG, , Hochstrasse 201, . Schaffhausen Schaffhausen(S witzerland) - CH- 8200	1 Vial of 25mg	3081.38/ 1Vial/Amp	Rupees Three Thousand EightyOne Paise ThirtyEight Only	L1
164	Johnson & Johnson Pvt. Ltd.	NLEM316	Risperidone Inj(Long acting)- Each Amp to contain: Risperidone 37.5 mg Packing: 1 Vial/Amp	1 Vial/Amp	Risperdal Consta® 37.5 mg Mfg.By:M/s. Cilag AG, , Hochstrasse 201, - Schaffhausen Schaffhausen(S witzerland) - CH- 8200	1 Vial of 37.5mg	4229.31/ 1Vial/Amp	Rupees Four Thousand Two Hundred TwentyNine Paise ThirtyOne Only	L1
164	Micro Labs Ltd	NLEM318	Risperidone Tab- Each Tab to contain: Resperidone 4mg	1 Tab	RISPOND-4	10's Tabs	2.00/ 1 Tab	Rupees Two Only	L1
164	MICRON PHARMACEUTICAL S	NLEM318	Risperidone Tab- Each Tab to contain: Resperidone 4mg	1 Tab	Same as in Item	10 Tab.	2.34/ 1 Tab	Rupees Two Paise ThirtyFour Only	L2
164	Intas Pharmaceuticals Ltd	NLEM318	Risperidone Tab- Each Tab to contain: Resperidone 4mg	1 Tab	RISDONE 4	10 Tab	2.62/ 1 Tab	Rupees Two Paise SixtyTwo Only	L3

  
उप चिकित्सा आयुक्त (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	GALPHA LABORATORIES LIMITED	NLEM320	Salbutamol Oral liquid-Each 5ml to contain:Salbutamol 2 mg, Packing:100ml bottle	1ml	Same as in Item	100 ml bottle	0.13/1ml	Paise Thirteen Only	L1
164	Hindustan Laboratories Limited	NLEM322	Salbutamol Tab- Each Tab to contain:Salbutamol 4 mg	1 Tab	HIBUTAMOL-4	10 Tablets Strip	0.17/1 Tab	Paise Seventeen Only	L1
164	Cipla Ltd.	NLEM329	Sodium Valproate Modified Release Tab- Each Tab to contain: Sodium Valproate 300mg	1 Tab	VALTEC CR 300	Strip of 10's Tabs	1.87/1 Tab	Rupee One Paise EightySeven Only	L1
164	Intas Pharmaceuticals Ltd	NLEM329	Sodium Valproate Modified Release Tab- Each Tab to contain: Sodium Valproate 300mg	1 Tab	VALPROL CR 300	15 TAB	2.20/1 Tab	Rupees Two Paise Twenty Only	L2
164	UNICURE INDIA LTD	NLEM330	Sodium Valproate Tab- Each Tab to contain: Sodium Valproate 500mg.	1 Tab	Same as in Item	Strip of 10 Tabs	2.99/1 Tab	Rupees Two Paise NinetyNine Only	L1
164	Eris Lifesciences Limited	NLEM336	Telmisartan Tab- Each Tab to contain: Telmisartan 80mg	1 Tab	ERITEL 80	15'S Strip	1.31/1 Tab	Rupee One Paise ThirtyOne Only	L1
164	Cipla Ltd.	NLEM336	Telmisartan Tab- Each Tab to contain: Telmisartan 80mg	1 Tab	CRESAR 80	Strip of 10's Tabs	2.27/1 Tab	Rupees Two Paise TwentySeven Only	L2
164	LUPIN LIMITED	NLEM336	Telmisartan Tab- Each Tab to contain: Telmisartan 80mg	1 Tab	TELISTA 80	15 Tab	2.77/1 Tab	Rupees Two Paise SeventySeven Only	L3

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	MICRON PHARMACEUTICAL S	NLEM339	Tenofovir + Lamivudine + Efavirenz Tab- Each Tab to contain:Tenofovir Disproxil Fumarate 300mg, Lamivudine 300mg,Efavirenz 600 mg	1 Tab	Same as in Item	30 Tab	29.70/ 1 Tab	Rupees TwentyNine Paise Seventy Only	L1
164	Cipla Ltd.	NLEM340	Tenofovir Disproxil Fumarate + Lamivudine +Dolutegravir Tablet- Each Tab to contain:Tenofovir Disproxil Fumarate 300 mg, Lamivudine 300 mg, Dolutegravir 50 mg	1 Tab	CIPANEC	30's Tabs	11.43/ 1 Tab	Rupees Eleven Paise FourtyThree Only	L1
164	Cipla Ltd.	NLEM342	Tenofovir Tab- Each Tab to contain Tenofovir Disproxil Fumarate 300 mg	1 Tab	TENVIR	30's Tabs	5.80/ 1 Tab	Rupees Five Paise Eighty Only	L1
164	HAB PHARMACEUTICAL S & RESEARCH LTD	NLEM347	Tramadol Cap- Each Cap to contain:Tramadol 100 mg	1 Cap	TOPDOL	10x10 caps	1.25/ 1 Cap	Rupee One Paise TwentyFive Only	L1
164	ALPA LABORATORIES LTD	NLEM347	Tramadol Cap- Each Cap to contain:Tramadol 100 mg	1 Cap	Same as in Item	10 Cap	1.50/ 1 Cap	Rupee One Paise Fifty Only	L2
164	ALPA LABORATORIES LTD	NLEM351	Vancomycin Inj- Each Vial to contain: Vancomycin 1000mg Packing: 1 Vial	1 Vial	Same as in Item	1 Vial	236.00/ 1 vial	Rupees Two Hundred ThirtySix Only	L1
164	STANEX DRUGS AND CHEMICALS PRIVATE LIMITED	NLEM353	Vecuronium Inj- Each Vial to contain: Vecuronium 10mg Packing: 1 Vial	1 Vial	Vecronex 10	1 vial	60.39/ 1 vial	Rupees Sixty Paise ThirtyNine Only	L1

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
164	Cipla Ltd.	NLEM359	Warfarin Tab- Each Tab contain: Warfarin 1mg	1 Tab	Warf - 1	Strip of 30's Tabs	0.60/ 1 Tab	Paise Sixty Only	L1
164	Cipla Ltd.	NLEM360	Warfarin Tab- Each Tab contain: Warfarin 5mg	1 Tab	Warf - 5	Strip of 30's Tabs	0.73/ 1 Tab	Paise SeventyThree Only	L1
164	Biodeal Pharmaceuticals Ltd.	NLEM361	Xylometazoline Nasal drops- Contain Xylometazoline 0.05% Packing: 10ml Vial	1 ml	Same as in Item	10ML DROPPER BOTTLE	0.79/1 ml	Paise SeventyNine Only	L1

END OF RATE CONTRACT

  
उप चिकित्सा अधिकारी (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

क.रा.बी.नि.  
ESIC